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MicroRNAs (miRNAs) are small, non-coding RNAs that post-transcriptionally regulate
gene expression. Their altered expression and functional activity have been observed in
many human cancers. miRNAs represent promising diagnostic and prognostic molecular
biomarkers, and also serve as novel therapeutic targets.We performed a systematic analy-
sis of scientiﬁc reports that link differences in miRNA expression with the pathogenesis of
bladder cancer (BC). This literature review is the ﬁrst comprehensive database of miRNA
molecules with biased expression proﬁles in BC. Among the 95 differentially expressed
miRNAs that we identiﬁed from the literature, we classify 48 as up-regulated in BC, 35 as
down-regulated, and 12 as contradictory (contradictory data were reported in one or more
studies on the gene). In addition, we discuss the possible roles of differentially expressed
miRNAs in the regulation of intracellular signaling pathways in BC.
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MOLECULAR MARKERS OF BLADDER CANCER
Bladder cancer (BC) is one of the most common urogenital can-
cers. For example, approximately 386,300 new BC cases and
150,200 deaths caused by the BC worldwide were registered in
2008. The incidence of BC varies greatly among different geo-
graphic regions (ranges between 1.8 and 27.1 per 100,000 males
and 0.5 and 4.1 per 100,000 females) with the highest incidences
in countries where the dominant population is Caucasoid (Ploeg
et al., 2009). BC accounts for 3.1 and 1.8% of the overall can-
cer mortality in males and females, respectively. BC has many
known risk factors. As BC occurs more commonly in the elderly,
age is the major risk factor. The median ages of men and women
diagnosed with BC are 72 and 74 years, respectively (Jemal et al.,
2011). Cigarette smoking is another major risk factor for devel-
oping BC (Brennan et al., 2000). The relative risk of death from
BC among smokers is 2.75 for current smokers and 2.0 for former
smokers (Jacobs et al., 2010). Many chemicals are thought to be
carcinogens for BC, including aniline dyes and aromatic amines
(Vineis and Pirastu, 1997). Urinary tract infection, chronic irri-
tation from catheters or bladder stones, and a non-functioning
bladder are associated with an increased risk of squamous cell
carcinoma (SCC) of the bladder (Shokeir, 2004). Bladder infec-
tion by Schistosoma hematobium carries an increased risk of
BC, especially SCC, and is endemic in Egypt; inﬂammation is
thought to play an important role in carcinogenesis associated
with this parasite (Mostafa et al., 1999). Exposure to pelvic radia-
tion, for example in men with prostate cancer, appears to increase
the risk of BC (Sandhu et al., 2006). Strong epidemiologic evi-
dence does not exist for a hereditary cause of most BCs (Golijanin
et al., 2006).
Urothelial carcinoma of the bladder, the most common
histopathologic type of BC,has a variety of genetic and phenotypic
characteristics. Many genetic factors, such as chromosomal abnor-
malities, genetic polymorphisms, mutations, and epigenetic
alterations, contribute to tumorigenesis and the progression of
this type of cancer (Knowles, 2008). The most common genetic
alterations reported in these tumors are deletions on chromosome
9 and point mutations in ﬁbroblast growth factor (FGF) receptor
3 (FGFR3) and the alpha catalytic subunit of phosphatidylinos-
itol 3-kinase (PIK3CA). More than half of all bladder tumors
(all grades and stages) contain chromosome 9 alterations sug-
gesting that chromosome 9 genes may be involved in early tumor
development.
Many of these molecular peculiarities may serve as diagnostic
and/or prognostic markers of tumor growth, as well as signs of
disease progression. BC diagnostics can be based on the detec-
tion of molecular markers, which can provide detailed molecular
insight into the progression and metastasis of disease. The clinical
use of molecular markers can therefore lead to more accurate and
patient-speciﬁc prognoses and surveillance. In addition, the use of
biomarkers has the potential to improve the quality of life of BC
patients by limiting invasive and painful procedures traditionally
used to diagnose tumor growth.
At present, the most commonly used molecular markers of
BC are protein-coding genes and their products, which show
differential expression in tumor cells versus normal cells. These
genes include members of the RAS family [FGFR3, PIC3CA,
TP53, and others (Sidransky et al., 1991; Jebar et al., 2005)], as
well as differentially methylated DNA loci [for example, hyper-
methylated CDH1, RASSF1A, APC, CDH13, and other genes
(Maruyama et al., 2001)]. In this review, we systematically ana-
lyzed the peer-reviewed, scientiﬁc literature that reports the
identiﬁcation and characterization of microRNAmolecules (miR-
NAs) differentially expressed between cancerous bladders and
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normal bladders of men, and summarized the information in a
database.
Small non-coding RNAs are endogenous RNA molecules of
about 18–25 nucleotides in length that regulate gene expression
in many ways (Kaikkonen et al., 2011). There are several classes of
small RNAs like miRNAs, including PIWI interacting RNAs (piR-
NAs), small interfering RNAs (siRNAs), and others that are each
characterized by their different targets, mechanisms of matura-
tion, and action. In mammals, miRNAs are necessary for normal
development, cell growth, differentiation, apoptosis, and the regu-
lation of many other processes (Kusenda et al., 2006). miRNAs are
also known to play signiﬁcant roles in tumorigenesis. More than
50% of miRNA genes are located in cancer-associated genomic
regions or in fragile sites of the genome. Many types of cancer
are associated with aberrantly expressed miRNAs. Both losses and
gains of miRNA function contribute to cancer development and
continued tumor growth (Calin et al., 2004). miRNAs may act
as both oncogenes or tumor suppressors (Shenouda and Alahari,
2009). Furthermore, different cancer types, stages, and differ-
entiation grades may have unique miRNA expression proﬁles,
which make miRNAs potent biomarkers for cancer diagnosis
(Song and Meltzer, 2011; Corsini et al., 2012; Cortez et al., 2012;
Qi and Mu, 2012).
Here, we report the ﬁrst comprehensive database of BC-
associated miRNAs whose expression proﬁles are associated with
cancer. We performed a systematic search for published litera-
ture that reported the isolation and characterization of expres-
sion of BC-speciﬁc miRNAs. In the future, these differential
miRNA molecules may be used for developing BC diagnostic and
prognostic assays.
BC-ASSOCIATED miRNAs
Many diagnostic and prognostic biomarkers of BChave been iden-
tiﬁed over the past decade. Most of these are the biomarkers for
gene transcription, DNA methylation, or protein expression (Van
Tilborg et al., 2009). Since the examination of the function of miR-
NAs is a relatively new discipline in the biomedical sciences, there
exists a paucity of data on the prognostic role of miRNAs during
BC development. Thus, it is difﬁcult to evaluate the signiﬁcance
of miRNAs as indicators of tumor presence, growth, progression,
recurrence, development of metastasis, or patient survival. How-
ever, pioneering data reported by several research groups enable
the consideration of miRNAs as possible markers for the identiﬁ-
cation of BC patients with poor prognoses (those with the most
advanced stages of disease).
Using microarrays, quantitative real-time PCR (qRT-PCR), or
deep sequencing technologies, it is now possible to detect up-
and down-regulated miRNAs not only in cancerous or normal tis-
sues, but also in samples of urine, blood, or other biological ﬂuids
(Pritchard et al., 2012). Among the studies examined in the present
review, the most commonly up-regulated miRNA in BC was miR-
129 (Dyrskjot et al., 2009). In contrast, miR-145 and miR-133a
were reported to be down-regulated in cancer tissues, and these
two markers allowed the authors to distinguish cancer cells from
non-cancer cells with a sensitivity >70% and speciﬁcity >75%
(Ichimi et al., 2009). These down-regulated miRNA molecules
are known to function as tumor suppressors by negatively
regulating the expression of several oncogenes (Kent et al., 2010;
Moriya et al., 2012).
Yamada et al. (2011) investigated the expression of 27 miRNAs
in 104 BC tissues and in urine samples using miRNA microarray
proﬁling and qRT-PCR. Their study demonstrated that miR-96
and miR-183 concentrations in urine were signiﬁcantly correlated
with tumor stage and grade. These miRNAs, therefore, can be
regarded as promising diagnostic and prognostic BC markers. In
addition, expression of these miRNAs signiﬁcantly decreased after
radical surgery, suggesting that they can also be used as prognostic
molecular markers of cancer recurrence.
In another study (Wang et al., 2012), researchers analyzed
miRNA concentrations in urine sediment and urine supernatant
of BC and non-BC patients using qRT-PCR. The authors found
that the levels of miR-200 family members – miR-141, miR-155,
andmiR-429 – were lower in urine sediment in BC patients. Addi-
tionally, levels of miR-200a, miR-200b, miR-200c, miR-141, and
miR-429 in the urinary sediment increase signiﬁcantly following
surgery. In urine supernatant, the level of miR-192 was higher in
the control group, whereas the level of miR-155 was higher in the
cancer group. Levels of miR-200a, miR-200b, miR-200c, miR-141,
miR-429,miR-205,miR-192, andmiR-146a increased signiﬁcantly
after surgery. These ﬁndings suggest thatmiR-200-familymiRNAs
(miRs-141, -429, -192, -146a, -141, and others) are promising as
non-invasive, diagnostic, and prognostic markers.
In another study (Adam et al., 2012) miRNA levels were mea-
sured in the plasma of patients with or without BC. The authors
identiﬁed a total of 79 differentially expressed plasma miRNAs.
Some diagnostically relevant miRNAs, such as miR-200b, were
up-regulated in the BC patients, whereas others, such as miR-92
andmiR-33, were inversely correlated with the clinical stage of the
cancer. These ﬁndings support the notion that cell-free circulat-
ing miRNAs in the blood can be released in the bladder, as well
as in many other tissues (Allegra et al., 2012). Using a panel of
miRNA markers, the authors detected BC in the samples with up
to 89% accuracy, and with the accuracy of 92% for distinguishing
invasive BC samples from non-cancer samples. Finally, the accu-
racy of approximately 100% was demonstrated for distinguishing
muscle-invasive BC fromhealthy controls, and a 79%accuracywas
reported for three-way classiﬁcation between muscle-invasive BC,
non-muscle-invasiveBC,and controls. Strongprognostic relation-
ships were seen with upregulation of miRs-133b, -129, -518c, and
with a variety of other miRNAs (Dyrskjot et al., 2009). However,
further studies will be needed to validate this type of molecular
diagnostics.
miRNA BIOMARKERS FOR TREATMENT SELECTION
Differentially expressed miRNAs may regulate intracellular sig-
naling pathways. For example, it was demonstrated that this is the
case for two signaling pathways associated with BC progression.
Abnormal activation of the FGFR3 gene by means of either over-
expression or mutation can be found in approximately 80% of
non-invasive bladder tumors (Cappellen et al., 1999; Billerey et al.,
2001). FGFR3and several other growth factor receptors participate
in the activation of the RAS kinase signaling pathway. Activation of
this pathway leads to the increased cell proliferation, motility, and
cancer transformation through hyperplasia of normal urothelium
Frontiers in Genetics | Epigenomics and Epigenetics January 2013 | Volume 3 | Article 310 | 2
“fgene-03-00310” — 2013/1/2 — 19:43 — page 3 — #3
Zabolotneva et al. MicroRNA expression in human bladder cancer
(Figure 1). Using bioinformatic methods, it was predicted that
some miRNA molecules aberrantly expressed in BC actually tar-
get the FGFR3 gene product. Examples of this include miR-145,
miR-101, miR-99a, and miR-100. Furthermore, the regulation of
FGFR3 by miR-99a and miR-100 has been experimentally vali-
dated (Catto et al., 2009). Increased expression of miR-143 in BC
cells is accompanied by lower expression of RAS genes. Another
line of evidence recently conﬁrmed this by showing that induced
transcription of miR-143 in BC cell lines led to decreased expres-
sion of RAS (Lin et al., 2009; Kent et al., 2010). Another study
demonstrates that low expression of miR-7 is associated with the
hyperactive FGFR3 mutation status found in BC tissues (Veerla
et al., 2009).
The second major pathway engaged in BC progression is
misregulated in muscle-invasive tumors which mainly contain
mutations in the TP53 gene. So far there is no proven experimen-
tal data available on the role of differentially regulated miRNA
on the regulation of the p53 pathway. However, several miRNAs
that are frequently found to be aberrantly expressed in BC were
bioinformatically predicted to target p53 or some of its regulators
(Fendler et al., 2011). For example, MDM2 [p53-binding pro-
tein homolog (mouse)], MDM4 [Mdm2-p53-binding-protein
homolog (mouse)], and ataxia telangiectasia mutated (ATM) gene
products were predicted as targets for miR-10. Small RNA miR-
129 potentially targets the genesMDM4 andATM in this pathway;
miR-125b, miR-143, miR-30a/c, and miR-223 were predicted to
target p53 directly (Fendler et al., 2011). In agreement with these
ﬁndings, it was reported that expression levels of miR-10a, miR-
125b, and miR-222 may serve as predictors of muscle-invasive
carcinomas (Veerla et al., 2009).
Overall, these data indicate that non-invasive and muscle-
invasive carcinomas display speciﬁc miRNA patterns associated
with activation of different gene expression pathways. Thereby,
some miRNAs may act as markers of activated signaling path-
ways and therefore may point researchers to the key components
of the BC pathway. RNA proﬁling and selective targeting might,
in the future, allow health professionals to develop a personalized
approach to cure each tumor individually, therefore improving the
efﬁciency of BC therapy.
DATABASE OF miRNAs RELATED TO BC PROGRESSION
The major goal of the present review is to provide the most com-
prehensive list of miRNAs that are differentially expressed in BC.
These molecules can potentially be used as biomarkers for BC
FIGURE 1 |The two-pathway model of different types of bladder cancer development, and the miRNAs that regulate these pathways. miRNAs that
were reported to be down-regulated in BC are highlighted in red, and up-regulated miRNAs are highlighted in green. miRNA target genes are shown in blue in
front of the respective miRNA names.
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FIGURE 2 | Bladder cancer miRNA biomarker representation according to published data.
diagnosis, prognosis, and to inform treatment strategies. For this
purpose, we performed a search in the MedLine database for
papers using the search terms microRNA,miRNA, bladder, urothe-
lial, and cancer. Until October 2012, 101 such publications ﬁtting
this criterion were retrieved from the MedLine database. In spite
of the obvious signiﬁcance of miRNAs tumor progression, the rel-
atively sparse data on miRNAs in bladder oncology illustrate that
this area needs to be studied more intensively.
Literature review enabled us to identify a total of 95 miR-
NAs that are differentially expressed in BC, and seven miRNA
genes that were differentially methylated in the BC versus non-
cancer patients. Of the pool of a total of 95 RNAs, 35 miRNAs
(34%)were reported as down-regulated, 48 (47%) as up-regulated,
and 12 (12%) as “contradictory” (meaning, conﬂicting data were
reported in one or more studies). Interestingly, miR31 located in
9p21 genomic region, was reported to be homozygously deleted
in some BC cases (Veerla et al., 2009). This ﬁnding is in line with
the other published data that point to the deletions of chromo-
some 9 as the most common type of chromosomal alterations
in BC.
In addition, six miRNA genes were reported to be hypermethy-
lated in BC, while only one gene was reported as undermethylated
in BC (Figure 2). Of these, expression data in BC is available
for only one miRNA molecule (miR34). We summarized this
data in a publically available database (http://bladder.pparser.net/
MIRMarkers.php), which includes miRNA names, their roles in
BC, and primary literature studies with supporting expression
data.
This data clearly demonstrates that additional targeted, high-
throughput studies are needed to investigate the relationship
between miRNA expression and BC progression. The current
miRNA-based two-pathway model of BC development ignores
most of the reported differential miRNAs and, therefore, obvi-
ously does not reﬂect the complete picture of carcinogenesis in
the bladder. Contemporary high-throughput methods will most
likely enable ﬁnding far more participants of intracellular signal-
ing networks regulated by the differential miRNAs involved in BC
progression. Additionally, such studies would be of great utility to
researchers and practitioners alike, as they may not only validate
the previously published data, but also propose novel prospective
biomarkers for BC diagnostics.
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